Nektar Therapeutics (NKTR) Interest Expenses (2010 - 2026)

Nektar Therapeutics' Interest Expenses history runs 17 years deep, the most recent figure standing at $7.9 million for Q1 2026.

• In Q1 2026, Interest Expenses rose 59.67% year-over-year to $7.9 million; the TTM figure through Mar 2026 stood at $29.2 million (up 5.8% YoY), while the FY2025 annual figure was $892.4 million, up 3.88% from the prior year.
• Interest Expenses for Q1 2026 stood at $7.9 million, down from $9.8 million in the prior quarter.
• The five-year high for Interest Expenses was $10.2 million in Q4 2024, with the low at $5.0 million in Q1 2025.
• The 5-year median for Interest Expenses is $6.4 million (2024), against an average of $6.9 million.
• Peak annual rise in Interest Expenses reached 132.17% in 2022, while the deepest fall reached 45.68% in 2022.
• Nektar Therapeutics' Interest Expenses stood at $7.2 million in 2022, then decreased by 4.64% to $6.9 million in 2023, then surged by 47.85% to $10.2 million in 2024, then slipped by 3.78% to $9.8 million in 2025, then dropped by 18.7% to $7.9 million in 2026.
• Business Quant data shows NKTR's Interest Expenses at $7.9 million in Q1 2026, $9.8 million in Q4 2025, and $6.0 million in Q3 2025.